Coagulopathies Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Question | Answer |
Causes of vessel wall dz | Scurvy (Vit C def); Amyloidosis; Hereditary-Hemorrhagic Teleangiectasia (Osler-Weber-Rendu Dz); Neurofibromatosis; Collagen Dz (Marfan; Ehler-Danlos) |
micro-angiopathic hemolytic anemia (MAHA) lab findings | TTP; anemia, hemolysis, schistocytes |
Extrinsic & intrinsic coag pathways converge to form: | factor Xa |
All clotting factors (except FVIII) are made in: | Liver |
Effects of liver dz on coagulation | 1st: decrease in factor VII (short half-life) prolongs PT; then decrease in other factors -> prolonged aPTT. Disease causes splenomegaly -> thrombocytopenia |
MOA: warfarin tx on high PT | Warfarin antagonizes the action of Vitamin K |
Vitamin K is a necessary co-factor in the g-glutamyl carboxylation of: | Factors II, VII, IX, X (these along with Ca & platelets activate FX & FII in coag cascade). Also Protein C and Protein S |
MOA of vitamin K deficiency on high PT | Similar to MOA of warfarin |
Deficiencies in HMWK, PK, and FXII are assoc w/which bleeding problems? | Deficiencies in HMWK, PK, and FXII are NOT associated with any bleeding |
Clotting factor def assoc w/Jewish ancestry | FXI def |
Factor VIII deficiency AKA: | Hemophilia A |
Factor IX deficiency AKA: | Hemophilia B |
FVIII & FIX deficiency: percentages associated with bleeding & severity | <1% assoc w/ spontaneous bleeding. 1-5% moderate, can still have spontaneous bleed. 5-40% can bleed w/procedures or trauma |
Hx includes hemarthrosis, bleeding into joints, and/or x-linked FH of problems: | Factor IX deficiency; FVIII deficiency |
FVIII & FIX deficiency findings | Labs: aPTT prolonged; FVIII/FIX levels decreased |
FVIII & FIX deficiency mgmt | Specific factor replacements: FVIII or FIX concentrate (plasma derived or recombinant). Avoid IM injections or meds causing bleeding. |
FVIII Inhibitor | Seen in PG & the elderly; Presents with provoked – spontaneous bleeding; Rare ( 1:1,000,000); Auto-Ab vs FVIII, prevents fn or increasing clearance |
Treatment to Eradicate FVIII Inhibitor: | Steroids +/- Cyclophosphamide. Tx if Bleeding: If inhibitor is of low titer, can give FVIII; if titer is high, give FVIIa |
limited to mucocutaneous bleeding | vW Dz |
Functions of von Willebrand factor | Bridges platelets together and with endothelium. Carrier for FVIII, extending its half-life |
von Willebrand disease tx (for mild forms): | Avoid aspirin. DDAVP (synthetic vasopressin), intranasal or IV -> increase release of pre-formed vWF (only works for a day or two). e-aminocaproic acid works by inhibiting fibrinolysis |
von Willebrand disease tx (for Severe Bleeding/Surgery): | Replace with VWF:FVIII containing concentrates; Humate-P. DDAVP pre-op? |
Coagulation dz: causes elevated levels of prothrombin; leads to a modest increase in hypercoagulability, (2-fold) | Prothrombin 20210A Mutation |
Second most common inherited cause of hyper-coaguability | Prothrombin 20210A Mutation |
Prothrombin 20210A Mutation: concomitant risk factors | Smoking, BPCs/Hormone replacement |
Fibrinolysis/Anti-coagulant Disorders usu present as: | thrombosis |
Antithrombin activity is markedly stimulated by: | Heparin |
Antithrombin def is manifested by: | Recurrent venous thromboses |
Protein C or Protein S Def: Predisposition to: | recurrent venous thromboses |
Uncommon causes of venous thromboses | Antithrombin def; Protein C or Protein S Def |
Disease in which mutation causes resistance to inactivation by Activated Protein C | Factor V Leiden |
Most common hereditary hyper-coagulable state; mainly limited to ? | Factor V Leiden; pts of Euro extraction |
Factor V Leiden: Heterozygous state increases risk of thrombosis up to: | 8-fold |
Factor V Leiden: Homozygous state increases risk: | 100-fold |
Auto-antibody that interferes with the natural anti-coagulant system | Anti-Phospholipid Syndrome |
Anti-Phospholipid Syndrome presents with: | Recurrent arterial or venous thromboses; 2nd trimester miscarriages; Thrombocytopenia; Valvular heart dz |
Anti-Phospholipid Syndrome: Lab Data: | Presents w/prolonged aPTT (b/c in vitro fx of the Ab on aPTT); mixing study fails to normalize; Confirmatory tests required to make the diagnosis |
Anti-Phospholipid Syndrome: tx | Once thrombotic event occurs, tx w/warfarin indefinitely |
Condition in which circulating plasma (which contains clotting factors) turns into serum | DIC |
DIC: presentation | Excessive thrombosis (small-midsize vessels: organ infarcts); organ dysfunction (renal; hepatic; CNS: hematuria, GIB, petechiae); bleeding, shock, death |
Acral ischemia seen in: | DIC |
Hx pos for heparin, tacrolimus, ticlopidine may point to: | DIC |
Signs of hemorrhage in DIC | Mucous membranes; IV Sites, catheters, ETT; venipuncture sites |
DIC tx (if bleeding, or surgery needed) | Platelets. PRBCs. Fibrinogen if <100 (Give cryo: worsen thrombosis if given alone, as cryo lacks AT and proteins C & S) |
Defn Hemorrhage: | failure to maintain hemostasis |
Defn Thrombosis: | failure to maintain fluidity |
Steps in forming the primary hemostatic plug: | Platelet adhesion; platelet aggregation; platelet surface activation & recruitment of other platelets; platelet release |
Thromboxane A2 is: | a potent stimulator of platelet aggregation & vasoconstriction |
Visible end product of coagulation = | Fibrin |
DIC tx | Treat underlying condition. Replace blood products PRN (platelets, FFP, cryo for fibrinogen, PRBCs, ATIII). Possibly heparin or LMWH |
Most common congenital disorder of hemostasis | von Willebrand (prevalence 1%) (2nd: hemophilia A) |
von Willebrand genetics | autosomal dominant |
von Willebrand factor is carrier protein for: | factor VIII. vWF patients have decreased factor VIII levels & prolonged PTT |
Glanzmann syndrome = | rare autosomal recessive. Deficiency in factors IIb/IIIa; platelets cannot aggregate. High bleeding time. |
Tx for Glanzmann syndrome | platelet transfusion |
Liver is the site of production of all clotting factors except: | factor VIII |
Thrombopathies | Von Willebrand. Glanzmann thrombasthenia. Bernard-Soulier. Acquired |
Tx for liver dz/thrombocytopenia | FFP +/- cryoprecipitate (contains concentrated fibrinogen) |
Causes of acquired thrombopathy | Drugs (ASA, NSAIDS, cephalosporins); ETOH (>BT, >*PT, PTT also prolonged in end-stage liver dz); Renal dz (unknown mechanism); Dysproteinemias or MM |
Defn Thrombopathy (Qualitative) | Bleeding disorders characterized by prolonged BT despite normal platelet count |
Subacute DIC (Trousseau syndrome): will see: | Recurrent superficial & DVTs; low platelet & high D-dimer |
Natural anticoagulants | Proteins C & S |
Causes of vitamin K deficiency | biliary tract disease, drugs (Abx, warfarin), malnutrition, malabsorption |
Fibrinogen unique to: | plasma; ref range = 206-382 |
Factor Xa to monitor: | LMWH |
Hemophilia A & B clinical features | Hemarthroses (knees, ankles, elbows). Arthralgias. Low FVIIIc; high PTT. |
Hemophilia B clinical features | Christmas disease. X linked recessive; males; low FIX; high PTT. Tx = Factor IX, NO DDAVP, NO ASPIRIN |
Lupus Anticoagulant | Circulating IgG or IgM; high PTT (no correction with mixing studies); risk of thrombosis or recurrent spontaneous abortion |
Most frequent cause of hereditary thrombophilia | Factor V Leiden (AKA APC); hereditary resistance to action of activated protein C (4-8% of pop) |
Diff btw hep & LMWH | Hep binds to anti-thrombin III (inactivate coag factors); LMWH binds to ATIII and directly inactivates Xa |
D-Dimer | Nonspecific; only neg test is helpful; PE; 90% pts w/thrombotic & thromboembolic dz; Neg <0.349; Low Pos = 0.350-0.500; Positive = >0.500 |
Protein C def pts | warfarin hyper-sensitivity rxn; may have to decrease coumadin by half (lest get necrotizing condition) |
ACT | Activated clotting time; monitors heparin in OR (check if safe to pull cath/A lines); Normal blood clots in <100 seconds; Heparin therapeutic = 300-600 s |
Virchow's Triad | Vascular damage; Hypercoagulability; Vascular Stasis; Predisposes patient to venous thrombosis |
Distinguish liver disease coagulopathy from vitamin K deficiency | Vitamin K deficiency only: 5 is normal, 7 is low. Liver disease only: both 5 & 7 are low |
Spontaneous hemarthrosis may be sx of: | Hemophilia A |
Mucosal or gingival bleeding, epistaxis, menorrhagia | Von Willebrand dz |
Continuous bleeding post-op or trauma; s/p multiple blood transfusions; low platelets, increased PT, INR, + fibrin split products (increased D-dimer): | DIC |
Coag pathways | Intrinsic 12, 11, 9, 8; extrinsic 7; common 1,2,5, 10 |
thrombopathy genetics | von W auto dominant. Glanzmann and Bernard-Soulier auto recessive |
Trousseau syndrome = | subacute DIC in cancer pts |
hemophilia C | factor XI: x linked recessive, Ashkenazi; long PTT |
Vit K-dependent factors | 2, 7, 9, 10 |
heritable hypercoagulable states | Factor V Leiden; pro C & S deficiency; antithrombin III deficiency |
Hereditary resistance to action of activated protein C = | Factor V Leiden (APC resistance) |
Deficiency allows unopposed conversion of fibrinogen to fibrin = | Antithrombin III deficiency |
giant plts; auto rec; no von W factors | Bernard-Soulier dz |
Most common severe bleeding disorder | hemophilia A (low VIIIc) |
Hemophilia C (factor XI def) tx | FFP |
Von Willebrand Dz tx: | ddAVP (synthetic vasopressin); avoid aspirin |
Most common congenital coagulopathy | von Will (1% prevalence) |
Vitamin K deficiency is seen in: | HDN (tx with vitamin K). Malabsorption (of fat soluble vitamins: A,D,E, K). Malnutrition. Abx use |
Recurrent arterial or venous thromboses; 2nd trimester miscarriages; thrombocytopenia; valvular heart dz; suggests: | Anti-Phospholipid Syndrome |
fibrin is digested by | plasmin |
vWF is synthesized in: | endothelial cells & megakaryocytes |
Function of vWF: | mediate platelet adhesion to damaged vessel site |
Bernard-Soulier Syndrome | Rare autosomal rec; low/abn plt vWF receptor; giant plts, thrombocytopenia, prolonged BT |
The ___ pathway initiates coag process; then _____ pathway enhances _____ formation in clot | Extrinsic; intrinsic; thrombin |
First factors to be affected in hepatic dysfunction | Vit K dependent factors (2, 7, 9 & 10) + factor 5 |
DIC pathology | Consumption of coag factors 2/2 intravascular activation of coag process with secondary activation of fibrinolysis -> hemorrhage or thrombosis |
Common causes of DIC | Infectio (often GNR endotoxins), PG complications, massive tissue injury, hypoxia, acidosis, malignancy, snakebite, acute promyelocytic leukemia (M3 variant of AML) |
Hemophilia A epidemiology | X linked recessive: Males. 1 in 10,000 live births. 80% of hemophilia patients have Hemo A. |
Hemophilia B epidemiology | X linked recessive: Males. 1 in 30,000 live births. |
Hemophilia A mgmt | Factor VIII. DDAVP (transient rise in FVIII, leads to tachyphylaxis) |
Portal HTN can lead to: | splenomegaly, mild thrombocytopenia, varices, PUD, GI bleed |
Antithrombin III (ATIII) deficiency pathology | ATIII inactivates surplus thrombin. Activity potentiated by heparin. ATIII deficiency (AD or acquired) -> venous thrombosis |
ATIII deficiency mgmt | If VTE: IV heparin -> PO warfarin indefinitely |
Protein C deficiency pathology | Protein C = vit K-dependent liver protein to stimulate fibrinolysis & clot lysis. Deficiency -> recurrent VTE & PE. |
Protein C deficiency clinical features | Warfarin-induced skin necrosis. Purpura fulminans or fulminant intravascular coagulation in newborns. Possibly CVA. |
Protein C deficiency mgmt | IV heparin -> PO warfarin indefinitely |
What % of patients with DVT/PE have cancer? | 15% (another 5% without cancer dx will have cancer dx within 1 year) |
Created by:
Abarnard
Popular Medical sets